Key Points
- Director Stuart Kingsley bought 940 shares on March 6 at an average price of $31.86 for $29,948.40, raising his stake to 5,582 shares (a 20.25% increase), according to an SEC Form 4 filing.
- Shares fell about 7.1% to $30.48 with roughly 1.96M shares traded; the stock has a market cap of ~$3.81B, a P/E of 18.53, and a 52-week range of $8.64–$38.00.
- Indivior beat Q4 expectations with EPS $0.82 vs. $0.65 and revenue $358M vs. $305.6M, and analysts hold a consensus "Moderate Buy" rating with a $39.33 average price target.
Indivior PLC (NASDAQ:INDV - Get Free Report) Director Stuart Kingsley acquired 940 shares of the business's stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the purchase, the director directly owned 5,582 shares of the company's stock, valued at $177,842.52. This represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Indivior Stock Down 7.1%
NASDAQ:INDV traded down $2.35 during trading hours on Thursday, reaching $30.48. 1,964,837 shares of the stock were exchanged, compared to its average volume of 1,976,938. The stock has a market capitalization of $3.81 billion, a P/E ratio of 18.53 and a beta of 0.83. The firm has a 50 day simple moving average of $33.93 and a 200-day simple moving average of $30.53. Indivior PLC has a 52 week low of $8.64 and a 52 week high of $38.00.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.17. The business had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. As a group, analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts have weighed in on INDV shares. Weiss Ratings raised shares of Indivior from a "hold (c)" rating to a "buy (b-)" rating in a report on Monday, March 2nd. Zacks Research downgraded shares of Indivior from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 13th. Northland Securities set a $50.00 price objective on shares of Indivior in a research note on Tuesday, January 20th. Morgan Stanley reissued an "overweight" rating and issued a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Finally, HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the company a "buy" rating in a report on Monday, January 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Indivior currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.33.
Check Out Our Latest Research Report on INDV
Hedge Funds Weigh In On Indivior
Several institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its holdings in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock worth $39,000 after acquiring an additional 460 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company's stock valued at $761,000 after purchasing an additional 700 shares during the period. Blue Trust Inc. grew its position in Indivior by 17.8% in the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company's stock worth $176,000 after purchasing an additional 733 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in shares of Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company's stock valued at $37,000 after purchasing an additional 781 shares during the period. Finally, Salomon & Ludwin LLC bought a new stake in shares of Indivior during the fourth quarter valued at approximately $30,000. Institutional investors own 60.33% of the company's stock.
About Indivior
(
Get Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
